Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: A double-blind controlled study

Diabetes Care

Volumn 17, Issue 10, 1994, Pages 1100-1109

  Hermann, Leif S ^a,b   Schersten, Bengt ^a   Bitzén, Per Olof ^a   Kjellström, Thomas ^a   Lindgärde, Folke ^a   Melander, Arne ^a  

^a LUND UNIVERSITY   (Sweden)

^b NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; CHOLESTEROL; DIURETIC AGENT; GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLACTATEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; LACTATE BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0027935577     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.17.10.1100     Document Type: Article

References (35)

1. Campbell IW: Sulphonylureas and metformin: efficacy and inadequacy. In New Antidiabetic Drugs. Bailey CJ, Flatt PR, Eds. London, Smith-Gordon, 1990, p. 33-51
2. Groop LC: Sulfonylureas in NIDDM. Diabetes Care 15:737-754, 1992
3. Hosker JP, Burnett MA, Davies EG, Harris EA, Turner RC: Sulphonylurea therapy doubles β-cell response to glucose in type 2 diabetic patients. Diabetologia 28:809-814, 1985
4. Jeng CY, Hollenbeck CB, Wu MS, Chen YDI, Reaven GM: How does glibenclamide lower plasma glucose concentrations in patients with type 2 diabetes? Diabetic Med 6:303-308, 1989
5. Rains SGH, Wilson GA, Richmond W, Elkeles RS: The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Med 5:653-658, 1988
6. Hermann LS, Karlsson JE, Sjöstrand Å: Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol 41:263-265, 1991
7. Hermann LS, Melander A: Biguanides: basic aspects and clinical uses. In International Textbook of Diabetes Mellitus. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, Eds. Chichester, Wiley, 1992, p. 773-795
8. Bailey CJ: Biguanides and NIDDM. Diabetes Care 15:755-772, 1992
9. McIntyre HD, Paterson CA, Ma A, Ravenscroft PJ, Bird DM, Cameron DP: Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin-dependent) diabetes mellitus. Aust NZ J Med 21:714-719, 1991
10. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 16:621-629, 1993
11. McAlpine LG, McAlpine CH, Waclawski ER, Storer AM, Kay JW, Frier BM: A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. Eur J Clin Pharmacol 34:129-132, 1988
12. DeFronzo RA: Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: a balanced overview. Diabetologia 35: 389-397, 1992
13. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929, 1992
14. Hermann LS: Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 13 (Suppl. 3):37-41, 1990
15. Higginbotham L, Martin FIR: Double-blind trial of metformin in the therapy of non-ketotic diabetics. Med J Austr 2:154-156, 1979
16. Peacock I, Watts R, Selby C, Tattersall RB: Serum C-peptide after 6 months on glibenclamide remains higher than during insulin treatment. Diabetes Res 6:57-59, 1987
17. Groop L, Widen E, Franssila-Kallunki A, Ekstrand A, Saloranta C, Schalin C, Eriksson J: Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32:599-605, 1989
18. World Health Organization: Diabetes, Mellitus: Report of a WHO Study Group. Geneva, World Health Organization, 1985 (Tech. Rep. Ser. no. 727)
19. Bitzén PO, Melander A, Schemén B, Svensson M: Efficacy of dietary regulation in primary health care patients with screening-detected hyperglycaemia. Diabetic Med 5:640-647, 1988
20. Arnqvist HJ, Karlberg BE, Melander A: Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes. Ann Clin Res 15(Suppl. 37):21-25, 1983
21. 1c. by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 32:1867-1872, 1986
22. Schmidt FH: Die enzymatische Bestimmung von Glucose und Fructose nebeneinander. Klin Wochenschr 39:1244-1247, 1961
23. Heding LG: A simplified insulin radioimmunoassay method. In Labelled Proteins in Tracer Studies. Donato L, Milhaud G, Sirchis J, Eds. Brussels, Euratom, 1966, p. 345-350
24. Heding LG: Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548, 1975
25. Wahlefeldt AW: Triglyceride determination after enzymatic hydrolysis. In Methods of Enzymatic Analysis. 2nd ed. Bergmeyer HU, Ed. New York, Academic Press, 1974, p. 1831
26. Röschlau P, Bernt E, Gruber W: Enzymatische Bestimmungen des Gesamtcholesterin im Serum. Z Klin Chem Klin Biochern 12:226-230, 1974
27. Danielsson B, Ekman R, Fex G, Johansson BG, Kristensson H, Nilsson-Ehle P, Wadstein J: Changes in plasma high-density lipoproteins in chronic male alcoholics during and after abuse. Scand J Clin Lab Invest 38:113-119, 1978
28. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
29. Laurell CB: Electroimmunoassay. Scand J Clin Lab Invest 29 (Suppl. 124):21-29, 1972
30. Noll F: L(+)lactate determination with LDH, GPT and NAD. In Methods of Enzymatic Analysis. 2nd ed. Bergmeyer HU, Ed. New York, Academic Press, 1974, p. 1475
31. Food and Drug Administration, Center for Drug Evaluation and Research: COSTART (Coding Symbols for Thesaurus of Adverse Reaction Terms), 1989
32. Groop LC, Barzilai N, Ratheiser K, Luzi L, Wåhlin-Boll E, Melander A, DeFronzo RA: Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 14:724-727, 1991
33. Stenman S, Melander A, Groop P-H, Groop LC: What is the benefit of increasing sulfonylurea dose? Ann Intern Med 118:169-172, 1993
34. Wåhlin-Boll E, Sartor G, Melander A, Scherstén B: Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 22:21-25, 1982
35. Hermann LS: Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 5:233-245, 1979